The Journal of antimicrobial chemotherapy
-
J. Antimicrob. Chemother. · Jul 2016
Randomized Controlled Trial Clinical TrialA randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing two regimens. ⋯ Although we found no differences between arms regarding PEP non-completion, poor adherence and adverse events were significantly higher in patients allocated to tenofovir disoproxil/emtricitabine plus ritonavir-boosted lopinavir. These data support the use of raltegravir as the preferred third drug in current PEP recommendations.